Intelligent Bilayer Tablets for Enhanced Stability and Efficacy
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine with cutting-edge technologies like AI, IoT, blockchain, and novel materials to create a more powerful system for tracking stability, optimizing storage, and personalizing dosing.
Background and Problem Solved
The original patent disclosed bilayer tablets with improved dissolution properties, but it lacked a comprehensive system for ensuring the tablets' stability and efficacy throughout their lifecycle. This inventive concept addresses the limitations of the original patent by incorporating advanced technologies to monitor and predict degradation pathways, optimize storage conditions, and provide personalized dosing.
Detailed Description of the Inventive Concept
The system comprises a blockchain-based data storage platform for secure and transparent tracking of tablet stability and efficacy data. IoT-enabled sensors monitor environmental conditions, and an AI-powered predictive analytics module identifies potential degradation pathways. Additionally, machine learning algorithms analyze data from IoT-enabled sensors to predict optimal storage conditions, minimizing degradation. A novel, hydrophobic material is incorporated into the tablet composition to enhance stability in humid environments. Furthermore, a blockchain-based patient data storage platform, an AI-powered dosing algorithm, and a IoT-enabled dispenser facilitate personalized dosing. AI-powered image analysis detects changes in tablet morphology, correlating them with efficacy data from clinical trials.
Novelty and Inventive Step
The integration of AI, IoT, blockchain, and novel materials with the original bilayer tablet composition constitutes a new and non-obvious inventive concept. The synergistic combination of these technologies provides a comprehensive system for ensuring tablet stability and efficacy, which is not addressed by the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different AI algorithms, incorporating additional IoT-enabled sensors, or utilizing various blockchain platforms. Variations of the tablet composition could involve different ratios of acetylsalicylic acid to pseudoephedrine or the incorporation of other active pharmaceutical ingredients.
Potential Commercial Applications and Market
The intelligent bilayer tablets system has significant commercial potential in the pharmaceutical industry, particularly in the areas of cold and flu treatments. The system's ability to ensure tablet stability and efficacy, optimize storage conditions, and provide personalized dosing could lead to improved patient outcomes, reduced costs, and increased market share.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/209 |
| A | A61 | A61J3/10 |
| A | A61 | A61K31/137 |
| A | A61 | A61K31/616 |
| A | A61 | A61K9/2009 |
| A | A61 | A61K9/2018 |
| A | A61 | A61K9/2054 |
| A | A61 | A61K9/2059 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and drug delivery systems, specifically oral bilayer tablet design with a focus on pharmaceutical composition, stability, and controlled release technologies
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or formulation engineer with expertise in tablet design, drug stability, materials science, and experience with computational and sensing technologies in pharmaceutical development
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies like AI, IoT, and blockchain with existing pharmaceutical formulation techniques represents a predictable extension of known methods for tracking and optimizing drug stability and delivery. The core pharmaceutical composition remains substantially similar to the source patent, with digital monitoring and personalization technologies added as incremental improvements. The technical variations represent standard engineering approaches to enhancing pharmaceutical product tracking and performance.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,684 |
|---|---|
| Title | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof |
| Assignee(s) | BAYER AKTIENGESELLSCHAFT |